These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38026207)

  • 1. Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2.
    Wang Q; Li Z; Guo Y; Mellis IA; Iketani S; Liu M; Yu J; Valdez R; Lauring AS; Sheng Z; Gordon A; Liu L; Ho DD
    iScience; 2023 Nov; 26(11):108254. PubMed ID: 38026207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants.
    Wang Q; Iketani S; Li Z; Liu L; Guo Y; Huang Y; Bowen AD; Liu M; Wang M; Yu J; Valdez R; Lauring AS; Sheng Z; Wang HH; Gordon A; Liu L; Ho DD
    Cell; 2023 Jan; 186(2):279-286.e8. PubMed ID: 36580913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temperature-dependent Spike-ACE2 interaction of Omicron subvariants is associated with viral transmission.
    Benlarbi M; Ding S; Bélanger É; Tauzin A; Poujol R; Medjahed H; El Ferri O; Bo Y; Bourassa C; Hussin J; Fafard J; Pazgier M; Levade I; Abrams C; Côté M; Finzi A
    mBio; 2024 Jul; ():e0090724. PubMed ID: 38953636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1.
    Hu Y; Zou J; Kurhade C; Deng X; Chang HC; Kim DK; Shi PY; Ren P; Xie X
    Emerg Microbes Infect; 2023 Dec; 12(2):2271089. PubMed ID: 37824708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
    Roe TL; Brady T; Schuko N; Nguyen A; Beloor J; Guest JD; Aksyuk AA; Tuffy KM; Zhang T; Streicher K; Kelly EJ; Kijak GH
    Microbiol Spectr; 2023 Mar; 11(2):e0033323. PubMed ID: 36877050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75.
    Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD
    Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Boland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; ; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    bioRxiv; 2024 Feb; ():. PubMed ID: 38045308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct evolution of SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 lineages combining increased fitness and antibody evasion.
    Planas D; Staropoli I; Michel V; Lemoine F; Donati F; Prot M; Porrot F; Guivel-Benhassine F; Jeyarajah B; Brisebarre A; Dehan O; Avon L; Bolland WH; Hubert M; Buchrieser J; Vanhoucke T; Rosenbaum P; Veyer D; Péré H; Lina B; Trouillet-Assant S; Hocqueloux L; Prazuck T; Simon-Loriere E; Schwartz O
    Nat Commun; 2024 Mar; 15(1):2254. PubMed ID: 38480689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular Evolutionary Analyses of the Spike Protein Gene and Spike Protein in the SARS-CoV-2 Omicron Subvariants.
    Nagasawa N; Kimura R; Akagawa M; Shirai T; Sada M; Okayama K; Sato-Fujimoto Y; Saito M; Kondo M; Katayama K; Ryo A; Kuroda M; Kimura H
    Microorganisms; 2023 Sep; 11(9):. PubMed ID: 37764181
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced evasion of neutralizing antibody response by Omicron XBB.1.5, CH.1.1, and CA.3.1 variants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal AR; Saif LJ; Oltz EM; Zhang B; Zhou T; Xu K; Gumina RJ; Liu SL
    Cell Rep; 2023 May; 42(5):112443. PubMed ID: 37104089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination
    Wang H; Xue Q; Zhang H; Yuan G; Wang X; Sheng K; Li C; Cai J; Sun Y; Zhao J; Lu J; Fang S; Yang Y; Zhang Y; Huang Y; Wang J; Xu JH; Jiang MX; Wang X; Shen L; Liu Y; Liu Q; Zhang Q; Wang S; Wang P; Qiu C; Ai J; Zhang W
    Emerg Microbes Infect; 2023 Dec; 12(2):2249121. PubMed ID: 37668156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Omicron XBB subvariants exhibit enhanced fusogenicity and substantial immune evasion in elderly population, but high sensitivity to pan-coronavirus fusion inhibitors.
    Xia S; Jiao F; Wang L; Yu X; Lu T; Fu Y; Huang Z; Li X; Huang J; Wang Q; Man Q; Xiong L; Jiang S; Lu L
    J Med Virol; 2023 Mar; 95(3):e28641. PubMed ID: 36890632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational Investigation of Selected Spike Protein Mutations in SARS-CoV-2: Delta, Omicron, and Some Circulating Subvariants.
    Roy U
    Pathogens; 2023 Dec; 13(1):. PubMed ID: 38276156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.
    Wilhelm A; Widera M; Grikscheit K; Toptan T; Schenk B; Pallas C; Metzler M; Kohmer N; Hoehl S; Marschalek R; Herrmann E; Helfritz FA; Wolf T; Goetsch U; Ciesek S
    EBioMedicine; 2022 Aug; 82():104158. PubMed ID: 35834885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extraordinary Evasion of Neutralizing Antibody Response by Omicron XBB.1.5, CH.1.1 and CA.3.1 Variants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711991
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion.
    Hossain A; Akter S; Rashid AA; Khair S; Alam ASMRU
    Microb Pathog; 2022 Sep; 170():105699. PubMed ID: 35944840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice.
    Shin KS; Kim BS; Chang S; Jung IK; Park H; Park S; Shin J; Kim JH; Han SJ; Park B; Kim JO; Lee JA; Lee TY; Kang CY
    Int J Antimicrob Agents; 2024 Mar; 63(3):107082. PubMed ID: 38163552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2.
    Qu P; Evans JP; Faraone JN; Zheng YM; Carlin C; Anghelina M; Stevens P; Fernandez S; Jones D; Lozanski G; Panchal A; Saif LJ; Oltz EM; Xu K; Gumina RJ; Liu SL
    Cell Host Microbe; 2023 Jan; 31(1):9-17.e3. PubMed ID: 36476380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A recombinant spike-XBB.1.5 protein vaccine induces broad-spectrum immune responses against XBB.1.5-included Omicron variants of SARS-CoV-2.
    He C; Alu A; Lei H; Yang J; Hong W; Song X; Li J; Yang L; Wang W; Shen G; Lu G; Wei X
    MedComm (2020); 2023 Jun; 4(3):e263. PubMed ID: 37125241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low Neutralizing Activities to the Omicron Subvariants BN.1 and XBB.1.5 of Sera From the Individuals Vaccinated With a BA.4/5-Containing Bivalent mRNA Vaccine.
    Nham E; Kim J; Lee J; Park H; Kim J; Lee S; Choi J; Kim KT; Yoon JG; Hwang SY; Song JY; Cheong HJ; Kim WJ; Park MS; Noh JY
    Immune Netw; 2023 Dec; 23(6):e43. PubMed ID: 38188597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.